You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKinsey
Express Scripts
AstraZeneca
Harvard Business School

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ODM-201

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for ODM-201

Trial ID Title Status Sponsor Phase Summary
NCT01317641 Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer Completed Endo Pharmaceuticals Phase 1/Phase 2 The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
NCT01317641 Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer Completed Orion Corporation, Orion Pharma Phase 1/Phase 2 The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201 in patients with castrate resistant prostate cancer.
NCT01429064 Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001 Completed Orion Corporation, Orion Pharma Phase 2 The purpose of this study is to evaluate safety and tolerability of ODM-201 in patients with castrate resistant prostate cancer.
NCT01688089 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers Completed Orion Corporation, Orion Pharma Phase 1 The purpose of this study is to evaluate the safety and tolerability of escalating doses of ODM-103 when given to healthy male volunteers.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for ODM-201

Condition Name

Condition Name for
Intervention Trials
Prostate Cancer 7
Healthy 5
Parkinson's Disease 4
Healthy Volunteers 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Prostatic Neoplasms 16
Parkinson Disease 5
Motor Neuron Disease 3
Amyotrophic Lateral Sclerosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ODM-201

Trials by Country

Trials by Country for
Location Trials
United States 101
Japan 42
United Kingdom 36
Germany 35
Brazil 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Ohio 6
Colorado 6
California 5
Maryland 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ODM-201

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 7
Phase 2 9
Phase 1/Phase 2 5
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Not yet recruiting 16
Completed 12
Recruiting 12
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ODM-201

Sponsor Name

Sponsor Name for
Sponsor Trials
Orion Corporation, Orion Pharma 30
Bayer 13
University of Nottingham 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 48
Other 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
McKesson
AstraZeneca
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.